GlassScriptPhysician profile
Matthew Trese
NPI 1174973416
$3,859.42
in general payments reported to CMS, 2019-2025
19 companies · $620 in 2025
The $620 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $435 · 2020: $198 · 2021: $180 · 2022: $219 · 2023: $471 · 2024: $1,736 · 2025: $620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,827.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $1,372.74 | 2023-2024 | Iluvien, Yutiq |
| Regeneron Healthcare Solutions, INC. | $633.85 | 2021-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $268.98 | 2021-2025 | Vabysmo |
| Alcon Vision LLC | $248.01 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $207.02 | 2022-2025 | Xipere, Visudyne |
| Abbvie INC. | $176.76 | 2024-2025 | |
| Coherus Oncology, INC. | $156.63 | 2023-2024 | |
| Carl Zeiss Meditec, INC. | $141.73 | 2019 | |
| Ani Pharmaceuticals, INC. | $139.85 | 2025 | Iluvien, Purified Cortrophin Gel |
| Regeneron Pharmaceuticals, INC. | $124.98 | 2019 | |
| Astellas Pharma US INC | $81.88 | 2024-2025 | Izervay |
| Genentech, INC. | $72.75 | 2024 | Vabysmo |
| Johnson & Johnson Surgical Vision, INC. | $57.87 | 2019 | |
| Eyepoint US, INC. | $57.40 | 2020-2021 | |
| Apellis Pharmaceuticals, INC. | $34.93 | 2024 | Syfovre |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $24.32 | 2023 | |
| Ivantis, INC | $23.53 | 2020 | |
| Glaukos Corporation | $21.17 | 2019 | |
| Dutch Ophthalmic, USA | $15.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Trese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.